Substituted phenidates

From PsychonautWiki
(Redirected from Phenidate)
Jump to navigation Jump to search

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Generic structure of a phenidate molecule.

Substituted phenidates (also known as phenidates) refer to a class of compounds that predominantly produce traditional stimulant effects when administered. A substituted phenidate may be defined as an ester of ritalinic acid and its analogs.


Substituted phenidates are a chemical class based upon the molecule methylphenidate. The molecular structure of methylphenidate is comprised of a phenethylamine core with a carbon chain substitution at the Rα position that links to the RN position, forming a piperidine ring. It also includes a substitution at the Rβ position of methyl acetate.


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Substituted phenidates primarily act as reuptake inhibitors of the monoamine neurotransmitters dopamine, norepinephrine, and to a much lesser degree, serotonin. One study found that all substituted phenidates inhibited the norepinephrine and dopamine reuptake transporters 4 to >1,000-fold more potently than the serotonin transporter.[1]

List of substituted phenidates

Compound R3 R4 RO Structure
Methylphenidate H H CH3 Methylphenidate.svg
Ethylphenidate H H CH2CH3 Ethylphenidate.svg
Isopropylphenidate H H CH(CH3)2 Isopropylphenidate.svg
Propylphenidate H H CH2CH2CH3 Propylphenidate.svg
4-Methylmethylphenidate H CH3 CH3 4-Methylmethylphenidate.svg
3,4-CTMP Cl Cl CH3 3,4-CTMP.svg
4F-MPH H F CH3 4F-MPH.svg
4F-EPH H F CH2CH3 4F-EPH.svg
Methylnaphthidate (HDMP-28) CH=CH- CH=CH- CH3 Methylnaphthidate.svg
Ethylnaphthidate (HDEP-28) CH=CH- CH=CH- CH2CH3 Ethylnaphthidate.svg

See also

External links



  1. Luethi, D., Kaeser, P. J., Brandt, S. D., Krähenbühl, S., Hoener, M. C., Liechti, M. E. (May 2018). "Pharmacological profile of methylphenidate-based designer drugs". Neuropharmacology. 134: 133–140. doi:10.1016/j.neuropharm.2017.08.020. ISSN 0028-3908.